PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomaticphospholamban R14del Carriers)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Oct 2019
Price : $35 *
At a glance
- Drugs Eplerenone (Primary)
- Indications Cardiomyopathies; Dilated cardiomyopathy
- Focus Therapeutic Use
- Acronyms i-PHORECAST
- 27 Sep 2019 Planned primary completion date changed from 1 Feb 2021 to 1 Mar 2021.
- 31 Aug 2018 Biomarkers information updated
- 07 May 2018 Planned End Date changed from 1 Apr 2020 to 1 Jul 2021.